Advertisement
Clinical Therapeutics
Advanced searchSave search
Research Article| Volume 30, SUPPLEMENT 3, S88-S89, 2008

How are biomarkers defined and validated?

  • Bryan Winchester
    Correspondence
    Address correspondence to: Bryan Winchester, PhD, Biochemistry Research Group, UCL Institute of Child Health at Great Ormond Street Hospital, University College London, 30 Guilford Street, London WC1N 1EH, United Kingdom.
    Affiliations
    UCL Institute of Child Health at Great Ormond Street Hospital, London, United Kingdom
    Search for articles by this author
DOI:https://doi.org/10.1016/S0149-2918(08)00365-2
How are biomarkers defined and validated?
Previous ArticleA new look at the pathogenesis of Pompe disease
Next ArticleThe role of current biomarkers in the management of lysosomal storage disorders
      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Biomarkers Definitions Working Group
        Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework.
        Clin Pharmacol Ther. 2001; 69: 89-95
        • Cox TM
        Biomarkers in lysosomal storage diseases: A review.
        Acta Paediatrica Suppl. 2005; 94: 39-42
        • Winchester B
        Are there useful biochemical markers of disease activity in lysosomal storage diseases.
        J Inherit Metab Dis. 2001; 24: 52-56
        • Mills K
        • Vellodi A
        • Morris P
        • et al.
        Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease.
        Eur J Pediatr. 2004; 163: 595-603
        • Weiss DJ
        • Dorris M
        • Loh A
        • Peterson L
        Dehydrogenase based reagentless biosensor for monitoring phenylketonuria.
        Biosens Bioelectron. 2007; 22: 2436-2441
        • Boot RG
        • Verhoek M
        • de Frost M
        • et al.
        Marked elevation of the chemokine CCL18/PARC in Gaucher disease: A novel surrogate marker for assessing therapeutic intervention.
        Blood. 2004; 103: 33-39
        • Park HG
        • Ham HO
        • Kim KH
        • Huh N
        Oligonucleotide chip for the diagnosis of HNF-1 alpha mutations.
        Biosens Bioelectron. 2005; 21: 637-644
        • Smit S
        • van Breemen M
        • Hoefsloot HC
        • et al.
        Assessing the statistical validity of proteomics based biomarkers.
        Anal Chim Acta. 2007; 592: 210-217

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0149-2918(08)00365-2

      Copyright

      © 2008 Excerpta Medica Inc. Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX